Novo Nordisk lifts 2026 guidance as Wegovy sales surge in Q1

Novo Nordisk reported its first‑quarter results, noting that sales and operating profit are expected to decline less than previously forecast.

The company said adjusted sales fell between 4% and 12% year‑on‑year, an improvement over the earlier 5%‑13% range, driven by strong uptake of its obesity drug Wegovy.

Wegovy generated 2.26 billion Danish kroner (about $354 million) in Q1, roughly double analysts’ consensus of 1.16 billion kroner, helping overall sales and operating income beat Wall Street expectations by 1% and 14%.

The upbeat results come as Novo faces pricing pressure and competition from Eli Lilly in the GLP‑1 market, prompting the firm to adjust its outlook while overhauling its leadership team.